Paul Cottu (Institut Curie, Paris, France) presented the findings from the UNICANCER-NeoPAL study at the ESMO 2017 Congress (8–12th September, Madrid, Spain), listen to the podcast now to discover all the details of the trial.

UNICANCER-NeoPAL is a study of letrozole and palbociclib in luminal cancer. The trial enroled postmenopausal women with stage II or III ER-positive, HER2-negative breast cancer who were not candidates for BCS. All patients were required to have either a PAM50 luminal B or luminal A profile with proven lymph node involvement. Of 184 screened women, 106 patients with stage II-IIIA, PAM50-ascertained LBC underwent parallel 1:1 randomisation to six courses of third generation chemotherapy comprised of FEC100 for 3 cycles plus docetaxel 100 for 3 cycles or to 19 weeks of letrozole at 2.5 mg/day plus palbociclib at 125 mg/day for four, three-week cycles. Surgery was performed at week 20.

Related content:

TAILORx: a practice-changing breast cancer trial

Personalized immunotherapy leads to complete response in metastatic breast cancer patient

Treasure trove of 110 genes linked to breast cancer discovered

You might also like